.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Fish and Richardson
Moodys
Johnson and Johnson
Federal Trade Commission
Cipla
Queensland Health
US Army
Merck

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064032

« Back to Dashboard
NDA 064032 describes TAZICEF, which is a drug marketed by Hospira and is included in two NDAs. It is available from one supplier. Additional details are available on the TAZICEF profile page.

The generic ingredient in TAZICEF is ceftazidime. There are seventeen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.

Summary for 064032

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 064032

Ingredient-typeCephalosporins

Medical Subject Heading (MeSH) Categories for 064032

Suppliers and Packaging for NDA: 064032

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAZICEF
ceftazidime
INJECTABLE;INJECTION 064032 ANDA Hospira, Inc. 0409-5092 0409-5092-16 25 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5092-16) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM
TAZICEF
ceftazidime
INJECTABLE;INJECTION 064032 ANDA Hospira, Inc. 0409-5093 0409-5093-11 10 VIAL, PATENT DELIVERY SYSTEM in 1 TRAY (0409-5093-11) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, PATENT DELIVERY SYSTEM

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL
Approval Date:Oct 31, 1993TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/VIAL
Approval Date:Oct 31, 1993TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Colorcon
Cipla
Chinese Patent Office
Boehringer Ingelheim
Baxter
Fish and Richardson
Medtronic
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot